Kiora Pharmaceuticals, Inc. (KPRX) Stock Price & Analysis
Kiora Pharmaceuticals, Inc. (KPRX) — MoonshotScore 21/100 (Weak band), calculated Nov 18, 2026. Price $0.821 (-0.47%), as of the Nov 19, 2026 trading session; market cap $3.63M.
Educational signal · not a buy or sell recommendation · How to read this
Kiora Pharmaceuticals, Inc. · KPRX · NASDAQ
Kiora Pharmaceuticals, Inc. is a clinical-stage specialty pharmaceutical company focused on developing therapies for ophthalmic diseases.
Price as of Nov 19, 2026
Key Statistics
MoonshotScore v2 · Kiora Pharmaceuticals (KPRX)
WeakWhy this rating? Method, drivers & history
Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.
- Business Quality — Is this a genuinely good business?
- Financial Safety — Could this blow up on me?
- Valuation — Am I paying a fair price?
- Growth Durability — Is the growth real and likely to last?
- Momentum — Is the market already moving on this?
A strong balance sheet, but bottom-tier quality and weak growth. The score also carries a risk penalty for a bankruptcy-risk score in the distress zone and losses on top of negative retained earnings. Business Quality: Poor; Financial Safety: Sound; Valuation: Fair; Growth Durability: Fading; Momentum: Slipping.
- quarterly revenue $1M (Q3 FY2026, quarter ended Sep 30, 2026)
- EPS beat 6 of the last 8 reports
- Altman Z -10.38 · Piotroski F 3
Holding back: weak fundamentals, soft growth, weak price trend
Helping: balance-sheet strength, an attractive price
What has the MoonshotScore done over time?
| Recorded | Score | Band |
|---|---|---|
| 31 | Weak | |
| 20 | Weak | |
| 21 | Weak | |
| 21 | Weak | |
| 21 | Weak | |
| 21 | Weak |
Daily score refresh is delayed. This is the last recorded calculation.
Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.
Computed · How the MoonshotScore is computed →
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $0.821 | |
| Change on the day | -0.47% | |
| 52-week range | $0.821 – $2.91 | |
| Market capitalisation | $3.63M | — |
| Shares traded on the day | 27.4K |
Price & events
Other perspectives
Council score for Kiora Pharmaceuticals (KPRX): perspectives
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
5-Factor Breakdown
Legends Council
1 lens, 1 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Nov 19, 2026
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Sep 11, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
On Sep 11, 2026, the Munger lens read the price at that time as undervalued against its own estimate of value.
Readings on this page are from Nov 20, 2026, except a card that shows its own read date.
What is Kiora Pharmaceuticals (KPRX), and what does it report?
Short answer
A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. Kiora Pharmaceuticals, Inc. (KPRX) is listed on NASDAQ. It employs 13 people and is led by Brian Strem. In Q3 FY2026 it reported revenue of $1M and net income of -$2M. The market values it at $3.63M.
What do the latest results show for Kiora Pharmaceuticals (KPRX)?
Short answer · as of
The most recent reported quarter, Q3 FY2026, carried revenue of $1M. Against analyst estimates the company has EPS beat 6 of the last 8 reports.
Quarterly income statement — 1 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q3 FY2026 | $1M | -$2M | -$0.28 (diluted) |
What are the financial strengths and risks for Kiora Pharmaceuticals (KPRX)?
Short answer · as of
The MoonshotScore pillars rate balance-sheet strength, an attractive price as strengths. What is holding it back is weak fundamentals, soft growth, weak price trend. The distress and quality screens read Altman Z -10.38 · Piotroski F 3. Trailing ratios: ROE -82.1% · ROA -57.0% · current ratio 7.91 · earnings yield -164.8%.
Data-derived red flags
- Listing risk — at $0.821 the shares sit below the $1.00 minimum bid NASDAQ requires for continued listing.
- Financial-distress signal — its Altman Z-Score of -10.38 sits in the distress zone (elevated bankruptcy risk).
- Negative return on equity (-82.1%) — the business is not currently generating profit on shareholder capital.
How does Kiora Pharmaceuticals compare with its peers?
Short answer
Kiora Pharmaceuticals's score ranks 13th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.
| Company | Price | Market value | Score |
|---|---|---|---|
| $15.13 Nov 18, 2026 | $2.03B | 97 5-pillar Nov 18, 2026 | |
| $13.33 Nov 18, 2026 | $471M | 91 5-pillar Nov 18, 2026 | |
| $9.28 Nov 18, 2026 | $552M | 91 5-pillar Nov 18, 2026 | |
| $3.06 Nov 19, 2026 | $258M | 90 5-pillar Nov 18, 2026 | |
| $42.53 Nov 18, 2026 | $801M | 88 5-pillar Nov 18, 2026 | |
| $15.26 Nov 18, 2026 | $85.5M | 82 5-pillar Nov 18, 2026 | |
| $11.25 Nov 18, 2026 | $102M | 82 5-pillar Nov 18, 2026 | |
| $3.89 Nov 18, 2026 | $169M | 72 5-pillar Nov 18, 2026 | |
| $1.88 Nov 19, 2026 | $178M | 69 5-pillar Nov 18, 2026 | |
| $9.30 Nov 18, 2026 | $546M | 68 5-pillar Nov 18, 2026 | |
| $8.14 Nov 19, 2026 | $796M | 63 5-pillar Nov 18, 2026 | |
| $3.13 Nov 19, 2026 | $481M | 60 5-pillar Nov 18, 2026 | |
| Kiora Pharmaceuticals (KPRX) — this page | $0.821 | $3.63M | 21 |
Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.
The records behind this page
Who holds the shares?
Institutional ownership reported through 13F filings.
Tracked investors
Which of the 16 named investors we follow held KPRX in their latest 13F filing, and what they did against the filing before it.
None of the 16 tracked investors reported KPRX in their latest 13F filing.
How to read these figures
These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.
Kiora Pharmaceuticals Stock: Key Questions Answered
These answers are editorial: 1 of these 9 answers is drawn from the KPRX research dossier (written Jun 15, 2026 by gpt-4o-mini); the other 8 are question templates that restate figures shown above. Figures in this section are not part of the source register.
What does the MoonshotScore mean for KPRX?
KPRX carries the MoonshotScore stated above — the Weak band. This is an educational research signal, not a buy or sell recommendation. The number comes from the five-pillar engine (business quality, financial safety, valuation, growth durability, momentum), re-ranked daily against sector peers.
Is KPRX a good stock to buy?
Stock Expert AI does not rate KPRX buy, sell or hold. Kiora Pharmaceuticals, Inc. carries a MoonshotScore, in the Weak band, a research rating against its peers rather than a forecast. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.
What is the KPRX stock price today?
The last price recorded for Kiora Pharmaceuticals, Inc. (KPRX), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What are the main risks for KPRX?
Kiora Pharmaceuticals, Inc. faces several risks, including regulatory approval risks associated with its clinical trials, which may impact the timeline for product commercialization.
What are the key factors to evaluate for KPRX?
Kiora Pharmaceuticals, Inc. (KPRX) holds a MoonshotScore in the low range. Strategic Partnerships: Kiora Pharmaceuticals may explore strategic partnerships or collaborations with larger pharmaceutical companies to enhance its research capabilities and market reach. Not financial advice.
How frequently does KPRX data refresh on this page?
KPRX's price is the last quote we recorded, from the Nov 19, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.
What has driven KPRX's recent stock price performance?
Kiora Pharmaceuticals, Inc. (KPRX) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Focused expertise in ophthalmic disease therapies. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider KPRX overvalued or undervalued right now?
Kiora Pharmaceuticals, Inc. (KPRX) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
Can I buy fractional shares of KPRX?
Fractional-share availability for Kiora Pharmaceuticals, Inc. (KPRX) depends on your brokerage, account and supported securities. Check the broker's current eligibility, minimums and fees before placing an order.
Machine-generated analysis by Stock Expert AI — model gpt-4o-mini, generated Jun 15, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources: the source register lists the 15 figures on this page — 7 from Financial Modeling Prep (FMP), 7 with no recorded source and 1 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.
Publication details and research sources
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com